Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: A clinical and translational study

Journal of Clinical Oncology

Volumn 25, Issue 15, 2007, Pages 1979-1985

  Münster, Pamela ^a   Marchion, Douglas ^a   Bicaku, Elona ^a   Schmitt, Morgen ^a   Ji, Hyun Lee ^a   DeConti, Ronald ^a   Simon, George ^a   Fishman, Mayer ^a   Minton, Susan ^a   Garrett, Chris ^a   Chiappori, Alberto ^a   Lush, Richard ^a   Sullivan, Daniel ^a   Daud, Adil ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIRUBICIN; HISTONE DEACETYLASE; NARCOTIC ANALGESIC AGENT; VALPROATE SEMISODIUM; ANTINEOPLASTIC ANTIBIOTIC; ENZYME INHIBITOR; VALPROIC ACID;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER PAIN; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; ENZYME INHIBITION; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HALLUCINATION; HEADACHE; HEARING LOSS; HUMAN; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPONATREMIA; LEUKOPENIA; LIVER DISEASE; LOADING DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; SOLID TUMOR; SOMNOLENCE; THROMBOCYTOPENIA; TINNITUS; TREATMENT RESPONSE; VESTIBULAR DISORDER; DRUG ANTAGONISM; DRUG COMBINATION; MIDDLE AGED; NEOPLASM; PATHOLOGY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DNA TOPOISOMERASES, TYPE II; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; EPIRUBICIN; FEMALE; HISTONE DEACETYLASES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; VALPROIC ACID;

EID: 34249937594     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.6165     Document Type: Article

References (36)

1. Grunstein M: Histone acetylation in chromatin structure and transcription. Nature 389:349-352, 1997
2. Marks P, Rifkind RA, Richon VM, et al: Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 1:194-202, 2001
3. Sandor V, Bakke S, Robey RW, et al: Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8:718-728, 2002
4. Kelly WK, O'Connor OA, Krug, LM, et al: Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923-3931, 2005
5. Marshall JL, Rizvi N, Kauh J, et al: A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2:325-332, 2002
6. Gilbert J, Baker SD, Bowling MK, et al: A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 7:2292-2300, 2001
7. O'Connor OA, Heaney ML, Schwartz L, et al: Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24:166-173, 2006
8. Byrd JC, Marcucci G, Parthun MR, et al: A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105:959-967, 2005
9. Bug G, Ritter M, Wassmann B, et al: Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 104:2717-2725, 2005
10. Reid T, Valone F, Lipera W, et al: Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 45:381-386, 2004
11. Ryan QC, Headlee D, Acharya M, et al: Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 23:3912-3922, 2005
12. Minucci S, Horn V, Bhattacharyya N, et al: A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells. Proc Natl Acad Sci U S A 94:11295-11300, 1997
13. Kim MS, Blake M, Baek JH, et al: Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63:7291-7300, 2003
14. Kurz EU, Wilson SE, Leader KB, et al: The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol Cancer Ther 1:121-131, 2001
15. Marchion DC, Bicaku E, Daud AI, et al: Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 92:223-237, 2004
16. Marchion DC, Bicaku E, Daud AI, et al: Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res 65:3815-3822, 2005
17. Tsai SC, Valkov N, Yang WM, et al: Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet 26:349-353, 2000
18. Fuino L, Bali P, Wittmann S, et al: Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2:971-984, 2003
19. Nimmanapalli R, Fuino L, Stobaugh C, et al: Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 101:3236-3239, 2003
20. Kuendgen A, Schmid M, Schlenk R, et al: The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 106:112-119, 2006
21. Pauer LR, Olivares J, Cunningham C, et al: Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest 22:886-896, 2004
22. Kramer OH, Zhu P, Ostendorff HP, et al: The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. Embo J 22:3411-3420, 2003
23. Gottlicher M: Valproic acid: An old drug newly discovered as inhibitor of histone deacetylases. Ann Hematol 83:S91-S92, 2004 (suppl 1)
24. Gurvich N, Tsygankova OM, Meinkoth JL, et al: Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64:1079-1086, 2004
25. Werling U, Siehler S, Litfin M, et al: Induction of differentiation in F9 cells and activation of peroxisome proliferator-activated receptor delta by valproic acid and its teratogenic derivatives. Mol Pharmacol 59:1269-1276, 2001
26. Cinatl J Jr, Cinatl J, Scholz M, et al: Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs 7:766-773, 1996
27. Hsieh J, Nakashima K, Kuwabara T, et al: Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells. Proc Natl Acad Sci U S A 101:16659-16664, 2004
28. Marchion DC, Bicaku E, Turner JG, et al: Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res 11:8467-8475, 2005
29. Marchion DC, Bicaku E, Daud AI, et al: In vivo synergy between topoisomerase II and histone deacetylase inhibitors: Predictive correlates. Mol Cancer Ther 4:1993-2000, 2005
30. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
31. Perucca E: Pharmacological and therapeutic properties of valproate: A summary after 35 years of clinical experience. CNS Drugs 16:695-714, 2002
32. Dutta S, Zhang Y, Selness DS, et al: Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers. Epilepsy Res 49:1-10, 2002
33. Michelotti A, Venturini M, Tibaldi C, et al: Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients. Breast Cancer Res Treat 59:133-139, 2000
34. Berman E, Casper ES, Howard J, et al: Phase II trial of 4′-epi-doxorubicin in patients with advanced malignant melanoma. Cancer Treat Rep 68:679-680, 1984
35. Rosenthal MA, Green M, Wiernik P, et al: Epirubicin has modest single-agent activity in head and neck cancer but limited activity in metastatic melanoma and colorectal cancer: Phase II studies by the Eastern Cooperative Oncology Group. Am J Clin Oncol 21:509-512, 1998
36. Lopez M, Perno CF, Papaldo P, et al: Phase II study of epirubicin in advanced malignant melanoma. Invest New Drugs 2:315-317, 1984